Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience.
about
Dose Titration Algorithm Tuning (DTAT) should supersede 'the' Maximum Tolerated Dose (MTD) in oncology dose-finding trials.Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trialsThe role of age on dose-limiting toxicities in phase I dose-escalation trials.Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events.Systems Pharmacology Model of Gastrointestinal Damage Predicts Species Differences and Optimizes Clinical Dosing Schedules.Lung, CNS and musculo-skeletal targeted therapy-induced toxicity: imaging features.Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents
P2860
Q33806551-9C794797-2328-4E8A-A6C3-DB84458CAFC6Q35462692-F77431F4-6903-4542-A2BA-928E12491B00Q36443880-E88399ED-B79F-474B-8F91-6D14DAEF690DQ36871155-D5C5C1FE-3AEF-4ADB-84EC-0C0807C23612Q37364612-0D420A06-0052-43F7-A182-F9F30BE0FAF6Q37552648-18782B8B-A48F-427C-AA36-F34AB941DF0AQ37570408-90165F2D-B900-4147-A1D3-A439088C6766Q41161589-5218AACF-F3F4-4F7C-A6A9-0A716F65016EQ46302099-F2C74343-72C8-4A83-B597-5570578EB3EDQ55380706-3CDCABD8-DEED-4E0B-B373-146248D2024BQ58552999-3FA81C65-0D47-4A87-BA92-676CCE6C600E
P2860
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Defining the risk of toxicity ...... s: a single centre experience.
@en
Defining the risk of toxicity ...... s: a single centre experience.
@nl
type
label
Defining the risk of toxicity ...... s: a single centre experience.
@en
Defining the risk of toxicity ...... s: a single centre experience.
@nl
prefLabel
Defining the risk of toxicity ...... s: a single centre experience.
@en
Defining the risk of toxicity ...... s: a single centre experience.
@nl
P2093
P2860
P356
P1433
P1476
Defining the risk of toxicity ...... s: a single centre experience.
@en
P2093
A Tjokrowidjaja
J S de Bono
L R Molife
P2860
P304
P356
10.1093/ANNONC/MDS030
P577
2012-03-09T00:00:00Z